Fish Oil-Derived DHA Reaches Brain but Does Not Prevent Cognitive Decline: Study Finds

Fish oil supplements are widely marketed for supporting brain health, but a new clinical trial suggests they may not protect against memory loss or Alzheimer's disease, even though the key omega-3 fatty acid they contain successfully reaches the brain.

A new study published in eBioMedicine followed 365 adults aged 55 to 80 who rarely ate fish and were considered at increased risk of Alzheimer's disease. Participants were randomly assigned to receive either a daily fish oil supplement containing 2,000 mg of docosahexaenoic acid (DHA), an omega-3 fatty acid important for brain function, or a placebo.

Researchers first examined whether DHA from the supplements could enter the brain. After six months, DHA levels in cerebrospinal fluid—the fluid surrounding the brain—increased by an average of 17%, confirming that the omega-3 reached its intended target.

Despite this, the supplements failed to produce measurable brain health benefits over the two-year study period. Participants taking DHA showed no improvements in memory or cognitive performance compared with those receiving a placebo. Brain scans also revealed that fish oil supplements did not slow shrinkage of the hippocampus, a brain region critical for memory that commonly deteriorates in Alzheimer's disease.

The researchers believe the findings indicate that simply increasing omega-3 levels through supplements is unlikely to prevent Alzheimer's. Instead, they suggest that omega-3s may work more effectively when consumed as part of an overall healthy dietary pattern, such as the Mediterranean diet, rather than as isolated supplements.

The team is now investigating why the brain can absorb DHA without translating it into cognitive benefits and whether factors such as genetics, age, diet, and overall health influence how the brain utilizes omega-3 fatty acids. They emphasize that maintaining regular physical activity, quality sleep, and a balanced diet remains the most effective strategy for supporting long-term brain health and reducing Alzheimer's risk.

REFERENCE: Yassine, H. N., et al. (2026). CNS target engagement of high-dose DHA supplementation in older adults at risk for dementia: a randomised, double-blind, placebo-controlled trial. eBioMedicine. DOI: 10.1016/j.ebiom.2026.106316. https://www.thelancet.com/journals/EBIOM/article/PIIS2352-3964(26)00198-2/fulltext